ClinicalTrials.Veeva

Menu

Excimer Light(308) Therapy for Resistant Alopecia Areata

A

Assiut University

Status

Not yet enrolling

Conditions

Alopecia Areata

Treatments

Device: excimer light

Study type

Observational

Funder types

Other

Identifiers

NCT06149936
alopecia areata with excimer

Details and patient eligibility

About

This study aimed to evaluate the efficacy and safety of the 308-nm excimer lamp in resistant AA treated with topical minoxidil .

Full description

Alopecia areata (AA) is a chronic, nonscarring, T-cell mediated autoimmune disease, presenting with localized or diffuse hair fall in hair-bearing areas. Approximately 1.7% of the population experience an episode of AA during their lifetime. Both sexes are equally affected, and most new cases are recorded below the age of 30 years . Excimer laser using high-dose monochromatic UV radiation can trigger apoptosis and induce immunological suppression through altering cytokine production such as IL-4, IL-10, prostaglandin E2, platelet-activating factor, and cis-urocanic acid. Benefits have only been seen with localized patches of AA, and regrowth of hair occurs only in treated areas .

Enrollment

20 estimated patients

Sex

All

Ages

18 to 55 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • ● Having multiple patches of AA.

    • Duration of alopecia >1 year
    • No topical or systemic treatment for the last 4 months
    • Agreement to regular visits for treatment and follow-up.

Exclusion criteria

  • ● A single form of AA.

    • Alopecia for <1 year.
    • Being on other modalities of treatment.
    • Treatment within the last 4 months.
    • Photosensitive disorders.
    • Pregnancy or breastfeeding.

Trial contacts and locations

0

Loading...

Central trial contact

hagar maher, master

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems